Neuro, Here's a theoretical question - let's say RD-1 had finished all dosing prior to when the DSMB discovered the problems in RD-2. Could they then decide to just add more subjects to RD-1, even though the trial was technically over? Are there any clinical trial regulations that would prevent them from doing that, I wonder? Thanks.
Market Data 
Markets 
AI
